Original Research Article

A Study of Fungal Septicaemia in New Born at Tertiary Care Hospital

Jitendra Kumar Chaudhary, Amit Kumar Singh[*],
Shamsheer Ali Teeto and Hariom Sharan

Department of Microbiology, Varunarjun Medical College, Banthra, Shahjahanpur, India

*Corresponding author

A B S T R A C T

Keywords

Candida, Fungal sepsis, Fungal blood stream infection, Neonates

Article Info

Accepted:
04 January 2019
Available Online:
10 February 2019

Candida species are a common cause of neonatal nosocomial bloodstream infections in infants and are a leading cause of infectious-related mortality in the neonatal intensive care unit (NICU). The objective of this study was to determine the predominant organisms, antifungal sensitivity patterns and clinical risk factors in neonatal fungal blood stream infection cases (BSI) admitted to our hospital. This is a retrospective study of all neonatal fungal BSI cases between May 2018 and October 2018. Fungal sepsis was found in 25/210 (11.9%) of cases. Non *Albicans candida* (NAC) species were responsible for 85% of cases with *Candida glabrata* 11 (44%) as the most predominant species. Other species isolated were *C. tropicalis* 5 (20%), *C. albicans* 4 (16%), *C. paraspinolosis* 3 (12%), *C. krusei* 1 (4%) and *C. Kodo* 1 (4%). Antifungal sensitivity results showed that most of the NAC isolates especially *Candida glabrata, Candida paraspinolosis* were resistant to flucanazole, than *Candida albicans*. Amphotericin B showed more sensitivity than FLK over NAC species. The increase in neonatal fungal BSI and resistant organisms highlights the need to reanalyze use of strict infection control strategies, appropriate preventive and therapeutic measures such as prophylactic antifungal use and a restrictive policy of antibiotic use.

Introduction

Candida species are a common cause of neonatal nosocomial bloodstream infections in infants and are a leading cause of infectious-related mortality in the neonatal intensive care unit (NICU) (1). Invasive candidiasis refers to systemic infection with *Candida* of either vital organs or normally sterile body fluid (blood, cerebrospinal fluid (CSF), or urine acquired by sterile catheterization or suprapubic aspiration). Significance of *Candida* spp in neonatal intensive care units (NICU) is increasingly

being recognized. It is the third most common cause of late onset sepsis in NICU patients and accounts for 9 to 13% of blood serum infections (BSI) in neonates.[1] Fungal sepsis should be suspected in a critically ill neonate with negative blood culture.[2] Until recently, *C. albicans* was by far the predominant species in most countries, responsible for 60% of all cases of candidemia. However, recently several countries around the world have witnessed a change in the epidemiology of Candida infections, characterized by a progressive shift from a predominance of *C. albicans* to non-albicans Candida species

notably *C. tropicalis, C. parapsilosis, C. krusei, C. guilliermondii* and *C. glabrata.*[3,4] This changing trend is a matter of concern due to the emerging resistance of the non-albicans species to azoles. There is growing evidence suggesting a role of increasing use of azole agents in this epidemiological shift. Several of these NAC species exhibit intrinsic resistance to traditional triazoles like fluconazole (FLK) and may also demonstrate cross resistance to newer triazoles.[5]

The sources of candidiasis in NICU are often endogenous following colonization of babies with fungi. About 10% of these babies get colonized in the first week of life and up to 64% babies get colonized by 4 weeks of hospital stay.[6] Administration of contaminated intravenous solutions, notably the solution for total parental nutrition (especially the intra-lipid) may result in NICU outbreaks. Spread may also occur from patient to patient or through a colonized health care worker.[7-9]

Apart from these a number of other factors including the use of indwelling devices, broad spectrum antibiotics, low birth weight (LBW), prematurity, gastrointestinal surgery, artificial ventilation, and/or history of fungal colonization contribute to the risk.[10] Clinical presentation of candidemia resembles sepsis syndrome and to establish a clinical diagnosis is difficult.[11,12] Signs of fungal sepsis include thrombocytopenia, lethargy, glucose instability, increasing ventilation requirement and apnoea.

End organ damage is more common and severe in systemic fungal infections and can involve the kidneys, joint, brain, lung, eyes, liver, spleen and bones.[13,14.] The renal manifestations can be in the form of acute renal failure, hypertension or flank masses. Endopthalmitis is a complication of invasive disease and needs urgent intervention.[15]

The objective of this study was to determine the different fungal pathogens, review their sensitivity patterns and clinical risk factors.

Materials and Methods

This retrospective study was conducted between May 2018 and October 2018 in a tertiary care NICU in our hospital. All new-born aged 0 to 28 days admitted in neonatal intensive care unit (NICU) from May 2018 to October 2018 in whom fungal organism was isolated in blood culture were recruited in the study. Empirical antibiotic used was retrieved from the study. Candidemia was defined as the presence of at least one positive blood culture containing pure growth of *Candida spp.* with supportive clinical features. Any growth indicated was sub-cultured on 5% sheep blood agar and Sabouraud's dextrose agar (SDA) with chloramphenicol (0.05%) and incubated at 37°C for a minimum of 48 hours up to two weeks.

The *Candida* spp. isolated was identified as per standard mycological techniques.[17] Preliminary identification was done by colony morphology on SDA, chromogenic media (Hichrome, Himedia Pvt. Ltd.), grown at 45°C, germ tube test, chlamydospore formation, and was confirmed by carbohydrate fermentation and assimilation tests.[17] Anti-Fungal sensitivity was performed for FLK (25 mg), and amphotericin B (AMB, 100 units) using disc diffusion method on Muller-Hinton agar supplemented with 2% glucose and methylene blue (5 mg/ml).[18,19] Zone diameters were interpreted as per the approved Clinical Laboratory Standards (CLSI) guidelines. Quality control for AFS was performed using *C. albicans*-ATCC 90028 and *C. parapsilosis*-ATCC 22019.[20]

Statistical analysis

Statistical analysis was done using Statistical Package for Social Sciences (SPSS) version

11 and the prevalence of organisms was determined and expressed in percentage.

Results and Discussion

Of the total 210 neonates included in the study fungal sepsis was found in (25/210) 11.9% of cases. NAC species were responsible for 85% of cases with *C. glabrata* 11 (44%) as the most predominant species. Other species isolated were *C. tropicalis* 5 (20%), *C. albicans* 4 (16%), *C.*

paraspinolosis 3 (12%), *C. krusei* 1 (4%) and C. *kodo* 1 (4%) (Table 1). Antifungal sensitivity results revealed that most of the NAC isolates especially *Candida glabrata, Candida paraspinolosis* were resistant to fluconazole than *Candida albicans*. AMP showed more sensitivity than FLK over NAC species (Table 2). Among the risk factor observed for candidemia (Table 3) were LBW, prematurity, prolonged antibiotic use, ventilator support and TPN as described below in Tables 3-4.

Table.1 Isolated candida species on the basis of culture and LPCB (n=25)

Organism	No of isolates	%
Candida glabrata	11	44
Candida tropicalis	5	20
Candida albicans	4	16
Candida parapselosis	3	12
Candida Krusei	1	4
Candida Kodo	1	4

Table.2 Anti-fungal susceptibility profile of *Candida* isolates (n=25)

S.No	Organism	FLK* n	(%)	AMB** n	(%)	Total no. of isolates
1	*Candida glabrata*	3	27.3	9	81.8	11
2	*Candida tropicalis*	3	60	5	100	5
3	*Candida albicans*	3	75	4	100	4
4	*Candida paraspinolosis*	2	66.7	3	100	3
5	*Candida krusei*	0	0	1	100	1
6	*Candida kodo*	1	100	1	100	1

FLK* - Fluconazole; AMB** - Amphotericin B.

Table.3 Potential risk factor for candidemia among neonates (n = 25)

	Frequency	(%)	Valid %	Cumulative (%)
<1 kg	5	20	20	20
1-1.5 kg	6	24	24	44
1.6-2.5 kg	5	20	20	64
>2.5 kg	9	36	36	100
Total	25	1000	100	

Table.4 Ventilator support among candidemia neonates (n=25)

	Frequency	(%)	(%)	Cumulative
<7days	2	8	8	8
7-14 days	4	16	16	24
>14 days	14	24	24	48
Not used	13	52	52	100
Total	25	100	100	

Fungal BSI is an important cause of morbidity and mortality in sick newborn infants. In the present study, isolation rate observed was 11.9%. This was comparable with study conducted by Rani *et al.,* where isolation rate was 11%.[21,22]

Of the total cases of neonatal candidemia, NAC species accounted for 85% of the cases, whereas *C. albicans* was responsible for 15% of cases. This corroborates well with the results of other authors23. Striking feature of the present study was isolation of *C. glabrata* (44%) as the most predominant NAC species followed by *C. tropicalis* (20%).

In recent years, there is marked shift in isolation rates of non-albicans Candida species compared to *Candida albicans* in cases of neonatal sepsis. Kossoff et al.[24] showed significant shift from *Candida albicans* to non-albicans, i.e. *Candida parapsilosis* over 15 years. Rani *et al.,* observed *Candida tropicalis* as predominant pathogen (92%), followed by *Candida albicans* and *Candida kefyr* (4% each).[24] All these findings are in contrast to present study which showed that Candida glabrata is emerging as predominant cause of neonatal sepsis.

This is in accordance with Karen *et al.,* which showed *Candida glabrata* as emerging pathogen.[25] Historically, *Candida glabrata* has been considered to be relatively non-pathogenic saprophyte of normal flora of healthy individuals rarely causing serious infections.[26] However, following widespread and increased use of immunosuppressive therapy, broad spectrum antibiotic therapy, increased conditions causing compromise of the immune system, the frequency of mucosal as well as systemic infections caused by *Candida glabrata* has increased significantly.[22,27]

Though *Candida glabrata* has emerged as important nosocomial pathogen, yet little is known about its epidemiology.[26] Infection with this species is associated with high-mortality rate.[25,26] *Candida glabrata* is of special importance because of its innately increased resistance to antifungal drugs, especially azoles.[25,26] The reasons behind emergence of the species as predominant pathogen could be because of selection of lesser susceptible species due to frequent use of fluconazole as prophylaxis.[27]

C. tropicalis causes infections with high mortality in adults and children with hematological malignancies or in immune-compromised individuals.[28] Ability of this organism to produce clusters is one of its major virulence factors. Once introduced into the immune-compromised host, *C. tropicalis* may be more virulent than *C. albicans* and can rapidly progress from colonization to invasion. It is the second leading cause of candidemia in adults, but is quite infrequent among neonates.[28] In the present study, *C. glabrata* and *C. tropicalis* have emerged as predominant species accounting for 72% of infected neonates.

AFS results showed that 27% of *C. glabrata* species were sensitive to FLK. High degree of resistance to azole compounds among *C. glabrata* species has been seen in many reports and can vary from 3.6% to 64%.[29,30] Resistance to AMB noted to be 19% is a matter of concern as emergence of such isolates may pose serious therapeutic challenges and also increases risk of nosocomial infection.

Combination of various risk factors is known to be strongly associated with development of candidemia. The major risk factors identified in our study were prematurity (60%), low birth weight (60%), prolonged antibiotic use (60%), ventilator support (56%) and total parenteral nutrition (50%).

Most of the neonates positive for candidemia were premature or low birth weight. This is in close agreement with many other reports.[23] Mechanical ventilation has well been described as a risk factor for the development of neonatal fungal blood stream infection. In present study, mechanical ventilation has a strong association for development of candidiasis in NICU admitted neonates than other studies.[23] Broad spectrum antibiotics were being administered to most of the neonates in the present study. They promote fungal overgrowth at the expense of normal bacterial flora and encourage translocation of yeast across the intact mucosa.

The risk of candidemia is known to increase exponentially with each class of antimicrobial used. Long term use of these broad-spectrum antibiotics must have created a negative pressure and favorable environment for Candida spp. to flourish. This substantiates the need of prophylactic antifungal to be used in a set up where continuous upsurge in the incidence of candidemia is seen.

In conclusion, fungal BSI is an important problem in neonates with a high mortality rate

and significant incidence of resistant organisms. Reporting of fungal BSI and the spectrum of species involved are essential measures in any ICU in order to implement appropriate preventive and therapeutic strategies. Antifungal susceptibility is very essential for effective treatment and the authors have also done susceptibility testing of their Candida isolates by disc diffusion test. Minimum inhibitory concentration (MIC) determination as per Clinical and Laboratory Standards Institute (CLSI) M27-A3 guidelines may be more reliable in such circumstances as also increasing the number of antifungals to include newer azoles (like ravuconazole, posaconazole) and echinocandins, as often some isolates are multidrug resistant (resistant across two antifungal classes). For echinocandins, disk diffusion is not recommended by CLSI.

As breakpoint MICs for some newer Candida species is still not defined by CLSI M27- A3, breakpoint suggested for yeast in CLSI M27-S4 can be used for such interpretations. Preventive measures such as use of filters for TPN, prophylactic antifungal use, and a restrictive policy of antibiotic use to decrease Candida colonization infection rates should be implemented to decrease mortality and morbidity associated with these infections. Also, previously ignored, NAC species esp *Candida glabrata* received little attention; therefore, not surprisingly our knowledge regarding them is not only incomplete, but also significantly lacking. So, we now need to have more studies and more tools; specially molecular tools to study the epidemiology of this emerging problem. Understanding the mechanisms of innate and acquired resistance may facilitate development of new targets for antifungal agents. Mechanical ventilation had well been described the risk factors played a significant role for the development of neonatal fungal blood stream infection as it is showed by the present study.

References

1. Benjamin DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, *et al.,* Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatr. 2006; 117(1): 84-92.

2. Baley JE. Neonatal candidiasis: the current challenge. Clin Perinatol. 1991; 18(2): 263-80.

3. Goel N, Ranjan PK, Aggarwal R, Chaudhary U, Sanjeev N. Emergence of non albicans Candida in neonatal septicemia and antifungal susceptibility: Experience from a reference tertiary care center. J Lab Physicians. 2009; 1(2): 53-5.

4. Oberoi JK, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Non-albicans *Candida* species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res. 2012; 136(6): 997-1003.

5. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among *Candida* spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol. 2006; 44: 529-35.

6. Huang YC, Li CC, Liu TY, Lien RI, Chou YH, Wu JL, *et al.,* Association of fungal colonization and invasive disease in very low birth weight infants. Paediatr Infect Dis J. 1992; 17: 819-22.

7. Robertson NR. Neonatal infections. In Robertson Textbook of Neonatology, 2nd edn. Churchill Living Stone; 1992: 984-5.

8. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very; low birth weight infants: clinical manifestations and epidemiology. Pediatr. 1992; 73: 144-52.

9. Libovitz E. Neonatal candidiasis: clinical picture, management controversies and consensus and new therapeutic options. J Antimicrobial Chemother. 2002; 49: 69-73.

10. Singhi S, Rao DS, Chakrabarti A. Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med. 2008; 9: 91-5.

11. Ariff S, Saleem AF, Soofi SB, Sajjad R. Clinical spectrum and outcomes of neonatal candidiasis in a tertiary care hospital in Karachi, Pakistan. J Infect Dev Ctries. 2011; 5: 216-23.

12. Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, *et al.,* Risk factors and predictors for candidemia in pediatric intensive care unit patients: Implications for prevention. Clin Infect Dis. 2010; 51: 38-45.

13. Benjamin DK, Ross K, McKinney RE, Benjamin DK, Auten R. When to suspect fungal infection in neonates: a clinical comparison of *Candida albicans* and *Candida paraspilosis* fungemia with coagulase - negative staphylococcal bacterimia. Paediatr. 2000: 106: 712-8.

14. Kler N, Garg P. Fungal sepsis. Bull Nat Neonatol Forum. 1999; 13: 13-5.

15. Davis LE. Fungal infections of the central nervous system. Neurol Clin. 1999; 17: 761.

16. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, *et al.,* Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003; 37: 1172-7.

17. McGinnis MR. Laboratory Handbook of Medical Mycology. New York: Academic Press. Yeast Identification; 1980: 337-73.

18. Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of *Candida* species. J Clin Microbiol. 1996; 34: 2154-7.

19. Kirkpatrick WR, Turner TM, Fothergill AW, McCarthy DI, Redding SW, Rinaldi MG, *et al.,* Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol. 1998; 36: 3429-32.

20. Pennysylvania, USA. Clinical Laboratory and Standards Institutes. Performance standards for antimicrobial susceptibility testings; twenty first informational supplement; 2011:100-S21.

21. Agarwal J, Bansal S, Malik GK, Jain A. Trends in neonatal septicemia: Emergence of non-albicans Candida. Indian Pediatr. 2004; 41: 712-5.

22. Rani R, Mohapatra NP, Mehta G, Randhawa VS. Changing trends of Candida species in neonatal septicemia in a tertiary north Indian hospital. Indian J Med Microbiol. 2002; 20: 42-4.

23. Sardana V, Pandey A, Madan M, Goel SP, Asthana AK. Neonatal candidemia: a changing trend. Indian J Pathol Microbiol. 2012; 55: 132-3.

24. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: Trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998; 17: 504-8.

25. Karen DF, Smita T, Erica S, Fernando MV. Neonatal *Candida glabrata* sepsis: Clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J. 2002; 22: 39-43.

26. Paul LF, Vanquez JA, Sobel JD. Candida glabrata: Review of epidemiology, pathogenesis and clinical disease with comparison to *C. albicans*. Clin Microbiol Rev. 1999; 12: 80-96.

27. Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross resistance in *Canduda glabrata*. J Clin Microbiol. 2006; 44: 1740-3.

28. Roilides E, Farmaki E, Evdoridou J, Francesconi A, Kasai M, Filioti J, *et al., Candida tropicalis* in a neonatal intensive care unit: Epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen. J Clin Microbiol. 2003; 41: 735-41.

29. Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, *et al.,* Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother. 2003; 47: 34-8.

30. Tseng Y, Lee W, Kuo T. *In-Vitro* susceptibility of fluconazole and amphotericin B against *Candida* isolates from women with Vaginal Candidiasis in Taiwan. J Food Drug Anal. 2005; 13: 12-6.